A recent review highlights how the Mediterranean diet can reduce inflammation and improve outcomes for chronic skin ...

In the treatment of psoriasis, preliminary evidence supports the hypothesis that IL-23 inhibitors are capable of extended remissions and protection against PsA relative to other biologics.

The still-growing list reflects recent advances in precision medicine that target specific components of the inflammatory cascade that drives psoriasis, including tumor necrosis factor (TNF)-alpha ...

IL-23, or IL-17 reduced serious infections, while tofacitinib increased infection risk, according to one study.

Until about 20 years ago, systemic treatment options for moderate/severe psoriasis were limited and nonspecific. To get an ...

The use of biologics in psoriasis and psoriatic arthritis management is not linked to the risk of cardiovascular or venous thromboembolic events.

Celltrion today announced the U.S. launch of STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab), following ...

Steqeyma is indicated for the treatment of plaque psoriasis and psoriatic arthritis in adult and pediatric patients, as well ...